» Articles » PMID: 17878350

Skin-derived Dendritic Cells Can Mediate Deletional Tolerance of Class I-restricted Self-reactive T Cells

Overview
Journal J Immunol
Date 2007 Sep 20
PMID 17878350
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Skin-draining lymph nodes contain a number of dendritic cell (DC) subsets of different origins. Some of these are migratory, such as the skin-derived epidermal Langerhans cells and a separate dermal DC subset, whereas others are lymphoid resident in nature, such as the CD8+ DCs found throughout the lymphoid tissues. In this study, we examine the DC subset presentation of skin-derived self-Ag by migratory and lymphoid-resident DCs, both in the steady state and under conditions of local skin infection. We show that presentation of self-Ag is confined to skin-derived migrating DCs in both settings. Steady state presentation resulted in deletional T cell tolerance despite these DCs expressing a relatively mature phenotype as measured by traditional markers such as the level of MHC class II and CD86 expression. Thus, self-Ag can be carried to the draining lymph nodes by skin-derived DCs and there presented by these same cells for tolerization of the circulating T cell pool.

Citing Articles

Effects of major OMPs and LPS of on the control of activation of bone marrow-derived dendritic cells and proliferation of T-lymphocytes in mice.

Xu Z, Tong Z, Zhang H, Deng X, Yang N, Wang Z Iran J Vet Res. 2025; 25(3):224-232.

PMID: 39925832 PMC: 11801326. DOI: 10.22099/ijvr.2024.48969.7177.


Cell shape sensing licenses dendritic cells for homeostatic migration to lymph nodes.

Alraies Z, Rivera C, Delgado M, Sanseau D, Maurin M, Amadio R Nat Immunol. 2024; 25(7):1193-1206.

PMID: 38834865 PMC: 11224020. DOI: 10.1038/s41590-024-01856-3.


Cotransfer of antigen and contextual information harmonizes peripheral and lymph node conventional dendritic cell activation.

Pirillo C, Al Khalidi S, Sims A, Devlin R, Zhao H, Pinto R Sci Immunol. 2023; 8(85):eadg8249.

PMID: 37478193 PMC: 7616026. DOI: 10.1126/sciimmunol.adg8249.


Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Jarvi N, Balu-Iyer S BioDrugs. 2021; 35(2):125-146.

PMID: 33523413 PMC: 7848667. DOI: 10.1007/s40259-020-00465-4.


Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Nussing S, Trapani J, Parish I Front Immunol. 2020; 11:589641.

PMID: 33072137 PMC: 7538772. DOI: 10.3389/fimmu.2020.589641.